Pharmaceutical - Mergers & Acquisitions

Filter

Current filters:

Mergers & Acquisitions

Popular Filters

126 to 150 of 642 results

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix

12-06-2014

Given the huge potential, and interest in, the hepatitis treatment market, and US pharma giant Merck…

Anti-viralsIdenix PharmaceuticalsMerck & CoMergers & AcquisitionsPharmaceutical

Allergan board again rejects revised unsolicited takeover bid from Valeant

Allergan board again rejects revised unsolicited takeover bid from Valeant

10-06-2014

US Botox-maker Allergan says that its board of directors, after consulting with its independent financial…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Celsion to acquire nucleic acid-based therapeutics firm EGEN

Celsion to acquire nucleic acid-based therapeutics firm EGEN

10-06-2014

US cancer drug developer Celsion Corp has entered into a definitive asset purchase agreement with EGEN,…

CelsionEGENMergers & AcquisitionsOncologyPharmaceutical

Allergan warns shareholders to take no action ahead of Valeant calling ‘special meeting’

Allergan warns shareholders to take no action ahead of Valeant calling ‘special meeting’

03-06-2014

Takeover target USA-based Allergan has responded to action taken by Canadian drugmaker Valeant Pharmaceuticals…

AllerganBusiness FinanceMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Endo completes sale of early-stage drug discovery portfolio

Endo completes sale of early-stage drug discovery portfolio

02-06-2014

Ireland-headquartered Endo Pharmaceuticals has completed the sale of its branded pharmaceutical drug…

AsanaBioSciencesEndo PharmaceuticalsMergers & AcquisitionsPharmaceutical

Roche to acquire Genia Technologies for up to $350 million

Roche to acquire Genia Technologies for up to $350 million

02-06-2014

Swiss drug major Roche said this morning that it plans to acquire Genia Technologies, a privately held…

Genia TechnologiesMergers & AcquisitionsPharmaceuticalRoche

Valeant goes even further, upping recently sweetened offer for Allergan

Valeant goes even further, upping recently sweetened offer for Allergan

02-06-2014

Even before it received an official response from its takeover target US Botox-maker Allergan, acquisitive…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Forest appeases shareholders over Actavis deal

30-05-2014

US drugmaker Forest Laboratories has reached a settlement with shareholders over its deal with generics…

ActavisBusinessBusiness FinanceEnvironmentForest LaboratoriesMajorMergers & AcquisitionsNew York Stock ExchangePharmaceuticalUSA

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

28-05-2014

The record start to 2014’s pharma M&A has been a welcome boost to a deal market that had been in the…

CancerGlobalInterviewsMergers & AcquisitionsPfizerPharmaceuticalPharmaceutical industryPharmaceutical sciences

Valeant ups offer for Allergan as target publishes attack on its business model

Valeant ups offer for Allergan as target publishes attack on its business model

28-05-2014

Canadian drugmaker Valeant Pharmaceuticals International has today upped its offer for USA-based Allergan…

AllerganBusiness FinanceBusiness FinanceCanadaMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

28-05-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceuticalValeant Pharmaceuticals

Is outsourcing the solution to the practical and business challenges facing pharma firms today?

Is outsourcing the solution to the practical and business challenges facing pharma firms today?

27-05-2014

Mergers and acquisitions within the pharmaceutical industry are nothing new, writes Alan Cox, chief executive…

AstraBusinessHealth Medical PharmaInterviewsMergers & AcquisitionsPharmaceuticalPharmaceutical sciencesPharmacology

AstraZeneca safe (for now?) as Pfizer walks away from pursuit of the firm

26-05-2014

US pharma giant Pfizer, which has been involved in a controversial pursuit of UK-based AstraZeneca, has…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pharmaceutical and life sciences deal volume up 53% in 1st-qtr, sets stage for heightened activity in 2014

21-05-2014

Pharmaceutical and life sciences (PLS) merger and acquisition (M&A) volume increased 53.1% in the first…

GlobalMergers & AcquisitionsPharmaceutical

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

19-05-2014

After what must have been a hectic weekend of cross Atlantic activity, the board of Anglo-Swedish drug…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Bayer divests interventional device business for $415 million

15-05-2014

German pharma and life sciences major Bayer has entered into a definitive agreement to sell its interventional…

BayerMergers & AcquisitionsPharmaceutical

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Cipla invests $1.5 million for 14.6% stake in USA’s Chase Pharma

14-05-2014

Indian drugmaker Cipla has said it will acquire a 14.6% stake in US-based Chase Pharmaceuticals for $1.5…

Chase PharmaceuticalsCiplaCPC 201Mergers & AcquisitionsNeurologicalPharmaceutical

Alliance Boots to acquire two major retail pharmacy networks in Latin America

14-05-2014

Alliance Boots, a multinational pharmacy-led health and beauty group, has recently signed an agreement…

Alliance BootsMergers & AcquisitionsPharmaceuticalSouth America

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

13-05-2014

As the arguments continue over the benefits or otherwise of US pharma giant Pfizer’s £63 billion ($106…

AstraZenecaMergers & AcquisitionsPfizerPharmaceuticalPoliticsUK

Patent expiry and increasing generic competition is expected to make a handful of mega deals happen

Patent expiry and increasing generic competition is expected to make a handful of mega deals happen

13-05-2014

The challenges posed by expiring patents, the global economic slowdown, and price premium pressures are…

Mergers & AcquisitionsPatentsPharmaceutical

Allergan board totally rejects Valeant’s $46 billion bid

Allergan board totally rejects Valeant’s $46 billion bid

13-05-2014

USA-based Allergan said yesterday that its board of directors has unanimously rejected the $46 billion…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

126 to 150 of 642 results

Back to top